The FLOW trial demonstrated meaningful reductions in kidney disease progression with semaglutide. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease. These are not trivial findings
Subsequent research has reinforced these concerning findings, with a Danish nationwide cohort study of 424,152 type 2 diabetes patients demonstrating that semaglutide doubled the five-year NAION risk compared to other treatments
LifeMD: Weight loss medication options Both Noom and LifeMD provide a path to getting GLP-1 medications for people who qualify
Most patients can safely continue GLP-1 medications before colonoscopy with appropriate precautions, including a 24-hour liquid-only diet before the procedure
your provider can discuss realistic expectations and supportive strategies
If you are considering semaglutide or similar medications and have concerns about how they might interact with your orthopedic care or recovery plan, we encourage you to schedule a consultation